Chief Executive Officer,
EGeen International Corp.
(Estonian Gene Bank Project)
Kalev Kask is the co-founder and CEO of EGeen International Corporation, a privately held U.S. biotechnology company. EGeen holds exclusive commercial rights to data from the Estonian Gene Bank Project, a national ongoing effort sponsored by the Estonian government to gather medical information and DNA samples from a significant portion of the population. This effort will create the most comprehensive health/gene/protein marker database of a representative population. Operating under a unique local law to ensure data confidentiality, EGeen will use the database for drug and diagnostic target discovery and personalized medicine applications, and to develop a pharmacogenetic platform.
Prior to founding EGeen International, Dr. Kask pursued neurobiology research at Stanford University and advised Asper Biotech and Toshiba on strategic development. After he completed his post-doctoral training at the Max-Planck Institute for Medical Research in Heidelberg, he joined the neurogenomics company AGY Therapeutics, Inc.
Dr. Kask has a graduate degree in neuroscience from Stockholm University.